{'fraction_non_alphanumeric': 0.02247191011235955, 'fraction_numerical': 0.003745318352059925, 'mean_word_length': 5.467741935483871, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Laboratory monitoring of heparin therapy.

Unfractionated heparin therapy is widely used as a treatment for thromboembolic (obstructive blood clots) disorders. Heparin therapy, or the amount of heparin administered, is determined based on the result of the activated partial thromboplastin time or APTT. There are many preanalytical and analytical variables that may affect the APTT, giving dramatically different APTT measurements from one laboratory to another. This results in a variance in the amount of heparin administered to the patient. In addition to the pre-analytical and analytical variables, clinical therapeutic range guidelines such as the standard “1.5 – 2 times the mean of the reference range”, almost always underestimate the amount of heparin required for adequate anticoagulation.